Health
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meetingVIVIAD analyses continue to support varoglutamstat’s potential in kidney disease, and consistently provide further evidence for a beneficial impact on kidney function based on its proposed mechanism of action Halle
About this update from Vivoryon Therapeutics N.v.
[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iv4MFFdTq5UwH.s30pVCjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025","length":133,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meeting","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"VIVIAD analyses continue to support varoglutamstat’s potential in kidney disease, and consistently provide further evidence for a beneficial impact on kidney function based on its proposed mechanism of action","length":208,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":359,"olType":false},{"type":"text","content":"","length":0,"tagName":"p","attribs":{}},{"type":"text","content":"Halle (Saale) / Munich, Germany, November 6, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced the presentation of clinical study data from the Company’s lead investigational medicine in development, varoglutamstat, in a late-breaking poster today, November 6, 2025, at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas.","length":541,"tagName":"p"},{"type":"text","content":"The poster titled “Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial” featured Phase 2 clinical study data underscoring varoglutamstat’s unique ability to stabilize and even improve kidney function, as measured by eGFR values.","length":316,"tagName":...